ĐÁNH GIÁ HIỆU QUẢ KIỂM SOÁT ĐƯỜNG HUYẾT CỦA THUỐC ỨC CHẾ SGLT-2 TRÊN BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TUÝP 2 ĐƯỢC ĐIỀU TRỊ NGOẠI TRÚ TẠI BỆNH VIỆN ĐA KHOA ĐỒNG NAI

Abstract

Objective: To evaluate the effectiveness of SGLT-2 inhibitors (SGLT-2i) in glycemic control in outpatients with type 2 diabetes. Methods: A retrospective cross-sectional descriptive study was conducted from 1/2023 to 6/2024 on 204 outpatients with type 2 diabetes using the SGLT-2i at the Dong Nai General Hospital. Results: Outpatients with type 2 diabetes had a median age of 67 years (61–71.75). The proportion of women was higher than that of men. The average number of drugs per prescription was 7 (5 - 8). Hypertension and dyslipidemia were two common comorbidities. Most patients with type 2 diabetes were prescribed combination therapies containing SGLT-2i. DPP-4 inhibitors and metformin were the most commonly combined agents with SGLT-2i. After treatment with regimens containing SGLT-2i, fasting blood glucose (FBG) and HbA1c concentrations were both improved. The proportion of outpatients achieving target HbA1c and FBG levels increased significantly (p < 0.05). Baseline HbA1c levels were associated with achieving target HbA1c levels (<7%) after treatment. Conclusion: Therapeutic regimens containing SGLT-2 inhibitors improved the proportion of outpatients achieving target HbA1c and fasting blood glucose levels.